Innate Pharma S.A. ADS (IPHA)
NASDAQ: IPHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
IPHA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $169.78M
- EPS (TTM)
- -$0.59
- Dividend yield
- None
- 52-week range
- 1.17 – 2.71
- Day range
- 1.50 – 1.55
- Volume / Avg
- 13.82K / 156.71K
- Beta
- —
- Shares outstanding
- 111.70M
- Next earnings
- Nov 5, 2026
52-week range
IPHA stock today
Innate Pharma S.A. (IPHA) closed at $1.52 on Oct 7, down 4.40% (-$0.07), versus the S&P 500's 0.22% decline. Trading was light, with 13.82K shares changing hands, about 9% of the average daily volume. At this level, IPHA sits in the middle of its 52-week range of $1.17 to $2.71: 43.9% below the high, set on Aug 13, 2026 and 29.9% above the low.
IPHA is down 13.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 22.1%. Innate Pharma S.A. has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful. Innate Pharma S.A.'s next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Innate Pharma S.A.
Company profileInnate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Jonathan E. Dickinson B.Sc., M.B.A.
- Headquarters
- Marseille
- Employees
- 120
- IPO year
- 2019
- Website
- innate-pharma.com
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$6.67+338.82%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
Innate Pharma S.A. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DTILPrecision BioSciences Inc. | 6.25 | +0.81% | $172.51M | vs IPHA |
| CRDLCardiol Therapeutics Inc. Class A | 1.32 | +0.76% | $160.40M | vs IPHA |
| CHRSCoherus Oncology Inc. | 1.01 | -1.94% | $156.05M | vs IPHA |
| CMPXCompass Therapeutics Inc. | 1.02 | +2.19% | $183.69M | vs IPHA |
| TARAProtara Therapeutics Inc. | 2.59 | +1.37% | $153.06M | vs IPHA |
| VYGRVoyager Therapeutics Inc. | 2.47 | +0.41% | $152.20M | vs IPHA |
| ABOSAcumen Pharmaceuticals Inc. | 2.10 | +3.45% | $151.87M | vs IPHA |
| MOLNMolecular Partners AG ADR | 3.81 | +0.79% | $145.94M | vs IPHA |
Indexes, lists and sector
Innate Pharma S.A. stock FAQ
What is Innate Pharma S.A.'s stock price today?
IPHA last traded at $1.52 as of Oct 7, 4:00 PM EDT, down 4.40% on the day. Prices are delayed at least 15 minutes.
When is Innate Pharma S.A.'s next earnings date?
Innate Pharma S.A. is expected to report earnings on Thursday, November 5, 2026.
Who is Innate Pharma S.A.'s CEO?
Mr. Jonathan E. Dickinson B.Sc., M.B.A. is the chief executive officer of Innate Pharma S.A. ADS, which has about 120 employees.
What is the IPHA 52-week high?
The 52-week high for IPHA is $2.71 and the 52-week low is $1.17. The stock is currently 43.9% below its high.